Skye Bioscience Inc. (SKYE)

Market Open

8 Dec, 20:36

NASDAQ (NMS)

1. 21

+0.01

+0.42%

41.98M Market Cap

- P/E Ratio

0% Div Yield

129,206 Volume

-0.9 Eps

$ 1.2

Previous Close

Day Range

1.18 1.23

Year Range

1.1 5.75

Want to track SKYE and more in your Portfolio? 🎯

Get Started For Free

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago

Skye Bioscience to discontinue development of eye disease treatment

Skye Bioscience said on Monday it intends to discontinue development of its experimental eye disease treatment after it failed in a mid-stage study.

Reuters | 1 year ago

Affiliate Program About Terms Privacy Help Contact Us